Free Trial
NASDAQ:GHRS

GH Research Q3 2026 Earnings Date & Estimates

GH Research logo
$18.23 -1.02 (-5.29%)
As of 10:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GH Research is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens

What Analysts Expect from GH Research in Q3 2026

GH Research is expected to post earnings of -$0.3122 per share. In the same quarter a year earlier GH Research reported -$0.23 per share. GH Research last reported on August 6, 2026, posting -$0.23 per share and beating the -$0.2860 consensus estimate. GH Research has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3122
Prior-Year EPS
-$0.23

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.23 (Beat by +$0.0560)
EPS Beat Rate
6 of last 8 quarters

GH Research Q3 2026 Earnings FAQ

GH Research (NASDAQ:GHRS) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

GH Research's Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect GH Research to post earnings of -$0.3122 per share for Q3 2026.

GH Research Earnings Headlines

GH Research PLC (GHRS) - What Are Brokerages Saying About This Stock?
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT.

Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

The company was established in 2018 and conducts clinical development to evaluate its candidates’ safety and potential benefits. Its work is aimed at addressing unmet needs in mental health care.

View GH Research Profile